Doctor of Philosophy in Pathology and Laboratory Medicine (PhD)

Overview

The UBC Department of Pathology and Laboratory Medicine offers a remarkable opportunity to study with numerous world renowned faculty and research programs. We are recognized as national and international leaders in both basic and clinical research. Experimental Pathology refers to research in any area of biomedical investigation that is relevant to human disease. Since it is necessary to understand the normal working of the system to fully define the changes associated with disease, the areas represented at UBC cover a wide range of fields and approaches. Work at all levels of biological organization is involved, from protein to lipoprotein biochemistry and molecular biology through cell and tumour biology, animal models for studies on pulmonary and cardiovascular pathophysiology and viral and bacterial infection processes, to clinical studies on human population and the AIDS epidemic.

We train students with varied backgrounds in science and medicine including: biochemistry, physiology, cell biology and microbiology/immunology.

We are committed to effective, cutting-edge, ethical research. The results of which will reach beyond the academic realm to effect positive change in the lives of our families, communities and, ultimately, our world.

Quick Facts

Degree
Doctor of Philosophy
Subject
Life Sciences
Mode of delivery
On campus
Registration options
Full-time
Specialization
Pathology and Laboratory Medicine
Program Components
Dissertation
Faculty
Faculty of Medicine

Apply Now

If you don't have a UBC Campus-Wide Login (CWL) please create an account first.
If you don't have a UBC Campus-Wide Login (CWL) please create an account first.

Program Enquiries

If you have reviewed the information on this program page and understand the requirements for this program, you may send an enquiry

Requirements

TOEFL (ibT) Overall Score Requirement

100
22
21
22
21

IELTS Overall Score Requirement

7.0
6.5
6.5
6.5
6.5

Supervisor commitment required prior to application?

Yes

GRE required?

Required by some applicants (check program website)

Deadline Details

Application Deadline

Deadline to submit online application. No changes can be made to the application after submission.

Transcript Deadline

Deadline to upload scans of official transcripts through the applicant portal in support of a submitted application. Information for accessing the applicant portal will be provided after submitting an online application for admission.

Referee Deadline

Deadline for the referees identified in the application for admission to submit references. See Letters of Reference for more information.

May 2020 Intake

Application Open Date
05 August 2019
Canadian Applicants
Application Deadline: 24 February 2020
Transcript Deadline: 02 March 2020
Referee Deadline: 02 March 2020
International Applicants
Application Deadline: 30 December 2019
Transcript Deadline: 06 January 2020
Referee Deadline: 06 January 2020

September 2020 Intake

Application Open Date
03 September 2019
Canadian Applicants
Application Deadline: 02 July 2020
Transcript Deadline: 09 July 2020
Referee Deadline: 09 July 2020
International Applicants
Application Deadline: 01 April 2020
Transcript Deadline: 09 April 2020
Referee Deadline: 09 April 2020

Funding Sources

All full-time students who begin a UBC-Vancouver PhD program in September 2018 or later will be provided with a funding package of at least $18,000 for each of the first four years of their PhD. The funding package may consist of any combination of internal or external awards, teaching-related work, research assistantships, and graduate academic assistantships. Please note that many graduate programs provide funding packages that are substantially greater than $18,000 per year. Please check with your prospective graduate program for specific details of the funding provided to its PhD students.

Career Outcomes

85 students graduated between 2005 and 2013: 1 graduate is seeking employment; for 8 we have no data (based on research conducted between Feb-May 2016). For the remaining 76 graduates:


RI (Research-Intensive) Faculty: typically tenure-track faculty positions (equivalent of the North American Assistant Professor, Associate Professor, and Professor positions) in PhD-granting institutions
TI (Teaching-Intensive) Faculty: typically full-time faculty positions in colleges or in institutions not granting PhDs, and teaching faculty at PhD-granting institutions
Term Faculty: faculty in term appointments (e.g. sessional lecturers, visiting assistant professors, etc.)
Sample Employers in Higher Education
University of British Columbia (15)
McGill University (2)
University of Oslo
University of Nebraska at Omaha
Langara College
Queensland Medical Research Institute
University Hospital of Geneva
Gulbenkian Institute of Science
University of North Dakota
Harvard University
Sample Employers Outside Higher Education
STEMCELL Technologies (2)
BC Centre for Disease Control (2)
NO
Dorsey & Whitney
Network Immunology Inc.
PROOF Centre of Excellence
Panagin Pharmaceuticals Inc.
Tekmire Pharmaceutical Corporation
Therapeutic Effectiveness and Policy Bureau
Ottawa Hospital Research Institute
Sample Job Titles Outside Higher Education
Scientist (5)
Senior Scientist (3)
Postdoctoral Fellow (2)
Medical Science Liaison (2)
Research Scientist (2)
Research Associate (2)
Research Specialist
Science Director
Researcher, Pathologist
Biomarker Program Manager
PhD Career Outcome Survey
You may view the full report on career outcomes of UBC PhD graduates on outcomes.grad.ubc.ca.
Disclaimer
These data represent historical employment information and do not guarantee future employment prospects for graduates of this program. They are for informational purposes only. Data were collected through either alumni surveys or internet research.
Career Options

An Experimental Pathology degree opens up a world of opportunities. Because of the multidisciplinary nature of our program, graduates are working on research all over the world that is personalized to their interests. Our alumni have gone on to become national and international opinion leaders, valued staff researchers and administrators in academia or the biotechnology industry, studied clinical medicine or dived into the venture capital and equities domain.

Alumni on Success

Xin Ye

Job Title
Research Scientist
Employer
Arbutus Biopharma Inc.

Erin Tranfield

Job Title
Head of the Electron Microscopy Facility
Employer
Instituto Gulbenkian de Ciência

Tuition / Program Costs

FeesCanadian Citizen / Permanent Resident / Refugee / DiplomatInternational
Application Fee$104.00$168.25
Tuition *
Installments per year33
Tuition per installment$1,665.26$2,925.58
Tuition per year
(plus annual increase, usually 2%-5%)
$4,995.78$8,776.74
Int. Tuition Award (ITA) per year (if eligible) $3,200.00 (-)
Other Fees and Costs
Student Fees (yearly)$930.14 (approx.)
Costs of living (yearly)starting at $16,884.10 (check cost calculator)
* Regular, full-time tuition. For on-leave, extension, continuing or part time (if applicable) fees see UBC Calendar.
All fees for the year are subject to adjustment and UBC reserves the right to change any fees without notice at any time, including tuition and student fees. Tuition fees are reviewed annually by the UBC Board of Governors. In recent years, tuition increases have been 2% for continuing domestic students and between 2% and 5% for continuing international students. New students may see higher increases in tuition. Admitted students who defer their admission are subject to the potentially higher tuition fees for incoming students effective at the later program start date. In case of a discrepancy between this webpage and the UBC Calendar, the UBC Calendar entry will be held to be correct.

Statistical Data

Enrolment Data

 20182017201620152014
Applications536109
Offers 1345
New registrations 1344
Total enrolment3541464749

Completion Rates & Times

This program has a graduation rate of 91.67% based on 12 students admitted between 2006 - 2009. Based on 15 graduations between 2015 - 2018 the minimum time to completion is 4.33 years and the maximum time is 7.00 years with an average of 5.53 years of study. All calculations exclude leave times.
Disclaimer
Admissions data refer to all UBC Vancouver applications, offers, new registrants for each year, May to April [data updated: 22 March 2019]. Enrolment data are based on March 1 snapshots. Program completion data are only provided for datasets comprised of more than 4 individuals. Rates and times of completion depend on a number of variables (e.g. curriculum requirements, student funding), some of which may have changed in recent years for some programs [data updated: 27 October 2019].

Upcoming Doctoral Exams

Wednesday, 4 December 2019 - 2:30pm - Dorothy Lam Boardroom, BC Cancer Research Centre, 675 West 10th Ave, Vancouver, V5Z 1L3

Jacky Kieran Leung
The Role of Proline Isomerase Pin1 in Regulating Transactivation of the Androgen Receptor N-Terminal Domain

Research Supervisors

This list shows faculty members with full supervisory privileges who are affiliated with this program. It is not a comprehensive list of all potential supervisors as faculty from other programs or faculty members without full supervisory privileges can request approvals to supervise graduate students in this program.

  • Luo, Honglin (Protein quality control in cardiac remodeling, Oncolytic virus for lung cancer therapy, Enteroviral infection and neurodegeneration)
  • Mackenzie, Ian (Alzheimer's Disease)
  • McManus, Bruce (Cardiovascular and pulmonary, genomic science, immunology, molecular pathology, detection of viral infection, heart and blood vessels )
  • Nielsen, Torsten (Translational research, Biomarker development, Experimental therapeutics, Clinical Trials, Epigenomics, Immuno-oncology)
  • O'Kusky, John (Neuroscience, embryology, mental health disorders )
  • Podor, Thomas (cardiovascular pathophysiology; endothelial cell proteolytic enzymes in the degradation of fibrin clots and extracellular matrix components; immunochemical and biochemical studies on the role of plasminogen activator inhibitor-1 (PAI-1) in thrombosis and fibrin clot degradation (fibrinolysis); thrombosis and thrombolysis )
  • Priatel, John (Autoimmunity, Immunodeficiency, Tumour immunotherapy, Viral infection, Host-pathogen interactions)
  • Schaeffer, David (Cancer, Molecular Pathology & Cell Biology, Genetics, genomics proteomics and related approaches, Gastrointestinal systems)
  • Schreiber, William (Porphyrias, toxicology, electrophoresis, educational technology, biochemistry, molecular biology)
  • Seow, Chun Yong (Airway smooth muscle, Contraction mechanism)
  • Shah, Sohrab (Interpretation of cancer genomes; Tumour evolution; Computational cancer biology; Bioinformatics)
  • Sorensen, Poul (Childhood cancer cells, genomic science )
  • Steidl, Christian (Cancer; Molecular Pathology & Cell Biology, Genetics, genomics proteomics and related approaches)
  • Takei, Fumio (Molecular immunology, cancer, cell-cell interactions)
  • Verchere, Bruce (Diabetes research, pediatrics, Beta cell survival and function)
  • Watson, Peter (biomarker)
  • Wellington, Cheryl Lea (Alzheimer's Disease, Traumatic Brain Injury, Tissue Engineering, Biomarkers, Drug Discovery, Apolipoprotein E, Cerebrovascular function)
  • Weng, Andrew (Molecular biology )
  • Wright, Joanne (Role of inflammation in the pathogenesis of chronic obstructive pulmonary disease, airways disease in asocation with mineral dusts and fumes, pulmonary vascular disease as a consequence of cigarette smoking, respiratory )
  • Yang, Decheng (Cardiovascular and pulmonary, infectious diseases, host gene responses to viral infections )

Pages

Recent Doctoral Citations

  • Dr. Charles Soong
    "Dr. Soong used DNA sequencing and mouse models to characterize drug sensitivities in cancer cells with faulty DNA repair machineries. Altogether, this study increased our understanding of the additional function of a pre-existing drug, with novel potential therapeutic targets." (May 2019)
  • Dr. Xining Yang
    "Dr. Yang developed a novel cell-free cancer therapeutic from bioreactor systems. She demonstrated that this therapeutic efficiently activated naive immune cells to kill cancer cells. The therapeutic consists of small natural molecules called microRNAs. Her research may result in a safer, faster and lower-cost approach for treating cancer." (May 2019)
  • Dr. Jonathon Kyle Obst
    "Dr. Obst investigated drug resistance in advanced prostate cancer. His work led to the recognition of a drug metabolism pathway exploited by resistant cells, and found that sensitivity could be restored using second-generation inhibitors. This study will hopefully aid in the development of novel compounds used to treat lethal prostate cancer." (May 2019)
  • Dr. Tianqing Tina Yang
    "Dr. Yang used advanced proteomics techniques to characterize cancer drug resistance, and to study the function of a tumour suppressor protein. These studies further our understanding of protein signalling pathways in cancer." (November 2018)
  • Dr. Kevin Chung-Hua Tsai
    "Dr. Tsai studied how the immune system in the gut responds to ingested particles. He found that gut leakiness can impact the development of the immune system. This work furthers our understanding on how ingested particles can potentially shape our immune system to control its responses towards food and the environment." (November 2018)

Sample Thesis Submissions

 

Apply Now

If you don't have a UBC Campus-Wide Login (CWL) please create an account first.
If you don't have a UBC Campus-Wide Login (CWL) please create an account first.
 

May 2020 Intake

Application Open Date
05 August 2019
Canadian Applicant Deadline
24 February 2020
International Applicant Deadline
30 December 2019

September 2020 Intake

Application Open Date
03 September 2019
Canadian Applicant Deadline
02 July 2020
International Applicant Deadline
01 April 2020
 

Supervisor Search

 

Departments/Programs may update graduate degree program details through the Faculty & Staff portal. To update the application inquiries contact details please use this form.